Epidemiology and Spatial Dynamics of NIE-ZAS-1 and Related Lineages in Nigeria, 2020–2025
Main Article Content
Keywords
cVDPV2, poliovirus, molecular epidemiology, Nigeria., NIE-ZAS-1, surveillance, spatial transmission
Abstract
Background: Nigeria continues to face persistent circulation of circulating vaccine-derived poliovirus type 2 (cVDPV2), driven by sustained transmission of dominant viral lineages and intermittent emergence of new strains. Since 2020, the NIE-ZAS-1 lineage has remained the most epidemiologically significant strain, with ongoing spread across multiple states. This study describes the temporal, spatial, and lineage-specific transmission dynamics of NIE-ZAS-1 and emerging related lineages between 2020 and 2025.
Methodology: We conducted a descriptive epidemiological and spatial analysis of poliovirus lineage surveillance data across Nigeria from 2020 to 2025. Genetic lineage classifications (NIE-ZAS-1, NIE-YBS-1, NIE-YBS-2, NIE-BOS-1, NIE-KTS-1) were analyzed by state, year, and quarter. Geographic diffusion patterns were reconstructed using state-level detection timelines, frequency counts, and directional spread from presumed origin states.
Results: NIE-ZAS-1 originated in Zamfara State in 2020 and expanded to at least 21 states by 2025, accounting for the majority of detections throughout the study period. Transmission showed marked seasonality, with consistent Q3 peaks. In contrast, newer lineages such as NIE-YBS-1, NIE-YBS-2, NIE-BOS-1, and NIE-KTS-1 demonstrated limited spatial spread and short-lived circulation, largely confined to Borno, Yobe, and Kano states. Despite reductions in case counts in some quarters, no lineage showed sustained interruption of transmission by 2025.
Conclusion: Persistent cVDPV2 transmission in Nigeria is driven predominantly by the long-standing NIE-ZAS-1 lineage, with emerging strains failing to replace but adding complexity to the transmission landscape. These findings underscore the need for geographically targeted, lineage-informed vaccination strategies, enhanced surveillance in origin and amplifier states, and intensified efforts during high-risk seasonal periods.
References
Aheto, J. M. K., Olowe, I. D., Chan, H. M. T., Ekeh, A., Dieng, B., Fafunmi, B., Setayesh, H., Atuhaire, B., Crawford, J., Tatem, A. J., & Utazi, C. E. (2023). Geospatial Analyses of Recent Household Surveys to Assess Changes in the Distribution of Zero-Dose Children and Their Associated Factors before and during the COVID-19 Pandemic in Nigeria. Vaccines, 11(12). https://doi.org/10.3390/vaccines11121830
Alleman, M. M., Jorba, J., Riziki, Y., Henderson, E., Mwehu, A., Seakamela, L., Howard, W., Kadiobo Mbule, A., Nsamba, R. N., Djawe, K., Yapi, M. D., Mengouo, M. N., Gumede, N., Ndoutabe, M., Kfutwah, A. K. W., Senouci, K., & Burns, C. C. (2023). Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017–2021. Vaccine, 41, A35–A47. https://doi.org/10.1016/j.vaccine.2023.02.042
Aylward, B., & Tangermann, R. (2011). The global polio eradication initiative: Lessons learned and prospects for success. Vaccine, 29(SUPPL. 4). https://doi.org/10.1016/j.vaccine.2011.10.005
Bammeke, P., Adamu, U. S., Bolu, O., Waziri, N., Erberto, T., Aregay, A., Nsubuga, P., Wiesen, E., & Shuaib, F. (2023). Descriptive epidemiology of poliomyelitis cases due to wild poliovirus type 1 and wild poliovirus type 3 in Nigeria, 2000-2020. The Pan African Medical Journal, 45, 4. https://doi.org/10.11604/pamj.supp.2023.45.2.38079
Bigouette, J. P., Henderson, E., Traoré, M. A., Wassilak, S. G. F., Jorba, J., Mahoney, F., Bolu, O., Diop, O. M., & Burns, C. C. (2023). Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2021–December 2022. MMWR. Morbidity and Mortality Weekly Report, 72(14), 366–371. https://doi.org/10.15585/mmwr.mm7214a3
Bricks, L. F., Macina, D., & Vargas-Zambrano, J. C. (2024). Polio Epidemiology: Strategies and Challenges for Polio Eradication Post the COVID-19 Pandemic. Vaccines, 12(12). https://doi.org/10.3390/vaccines12121323
Candido, D. da S., Dellicour, S., Cooper, L. V., Prete, C. A., Jorgensen, D., Uzzell, C. B., Voorman, A., Lyons, H., Klapsa, D., Majumdar, M., Arowolo, K., Peak, C. M., Bandyopadhyay, A. S., Martin, J., Grassly, N. C., & Blake, I. M. (2025). Historical and current spatiotemporal patterns of wild and vaccine-derived poliovirus spread. Nature Microbiology. https://doi.org/10.1038/s41564-025-02174-6
Cooper, L. V., Bandyopadhyay, A. S., Grassly, N. C., Gray, E. J., Voorman, A., Zipursky, S., & Blake, I. M. (2025). Global Impact of Mass Vaccination Campaigns on Circulating Type 2 Vaccine-Derived Poliovirus Outbreaks: An Interrupted Time-Series Analysis. Journal of Infectious Diseases, 231(2), e446–e455. https://doi.org/10.1093/infdis/jiae614
Cooper, L. V., Erbeto, T. B., Danzomo, A. A., Abdullahi, H. W., Boateng, K., Adamu, U. S., Shuaib, F., Modjirom, N., Gray, E. J., Bandyopadhyay, A. S., Zipursky, S., Okiror, S. O., Grassly, N. C., & Blake, I. M. (2024). Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study. The Lancet Infectious Diseases, 24(4), 427–436. https://doi.org/10.1016/S1473-3099(23)00688-6
Duintjer Tebbens, R. J., Hampton, L. M., & Thompson, K. M. (2016). Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of inadvertent trivalent oral poliovirus vaccine use. BMC Infectious Diseases, 16(1). https://doi.org/10.1186/s12879-016-1537-8
Effiong, F., Akanno, I. P., Anosike, U. G., Kayode, A. T., Okon, A. B., Iwendi, G. C., Oke, G. I., Nwobodo, M. A., & Ighodalo, U. L. (2021). Nigeria’s Polio Elimination Playbook: Lessons To Strengthening Health Systems For Other Eradicable Diseases. Global Biosecurity, 3. https://doi.org/10.31646/gbio.127
Fomban Leke, R. G., King, A., Pallansch, M. A., Tangermann, R. H., Mkanda, P., Chunsuttiwat, S., Jack, A., Kaboré, B. J., Kane, I., Khomo, N. E., Lopes-Feio, R. J., Maiga, Z. M., Matuja, W. B. P., Kironde, N. E., Kouassi, B., Sadrizadeh, B., & Tomori, O. (2020). Certifying the interruption of wild poliovirus transmission in the WHO African region on the turbulent journey to a polio-free world. The Lancet Global Health, 8(10), e1345–e1351. https://doi.org/10.1016/S2214-109X(20)30382-X
Gali, E., Mkanda, P., Banda, R., Korir, C., Bawa, S., Warigon, C., Abdullahi, S., Abba, B., Isiaka, A., Yahualashet, Y. G., Touray, K., Chevez, A., Tegegne, S. G., Nsubuga, P., Etsano, A., Shuaib, F., & Vaz, R. G. (2016). Revised household-based microplanning in polio supplemental immunization activities in Kano State, Nigeria. 2013-2014. Journal of Infectious Diseases, 213, S73–S78. https://doi.org/10.1093/infdis/jiv589
Initiative, E. (2004). Eradication Initiative 2004.
Kalkowska, D. A., Franka, R., Higgins, J., Kovacs, S. D., Forbi, J. C., Wassilak, S. G. F., Pallansch, M. A., & Thompson, K. M. (2021). Modeling Poliovirus Transmission in Borno and Yobe, Northeast Nigeria. Risk Analysis, 41(2), 289–302. https://doi.org/10.1111/risa.13485
Kalkowska, D. A., Pallansch, M. A., Wassilak, S. G. F., Cochi, S. L., & Thompson, K. M. (2023). Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine, 41, A136–A141. https://doi.org/10.1016/j.vaccine.2021.04.061
Kishore, N., Krow-Lucal, E., Diop, O. M., Jorba, J., Avagnan, T., Grabovac, V., Kfutwah, A. K. W., Johnson, T., Joshi, S., Sangal, L., Sharif, S., Wahdan, A., Tallis, G. F., & Kovacs, S. D. (2024). Surveillance To Track Progress Toward Polio Eradication — Worldwide, 2022–2023. MMWR. Morbidity and Mortality Weekly Report, 73(13), 278–285. https://doi.org/10.15585/mmwr.mm7313a1
Lee, S. E., Greene, S. A., Burns, C. C., Tallis, G., Wassilak, S. G. F., & Bolu, O. (2023). Progress Toward Poliomyelitis Eradication — Worldwide, January 2021–March 2023. MMWR. Morbidity and Mortality Weekly Report, 72(19), 517–522. https://doi.org/10.15585/mmwr.mm7219a3
Lopez Cavestany, R., Eisenhawer, M., Diop, O. M., Verma, H., Quddus, A., & Mach, O. (2024). The Last Mile in Polio Eradication: Program Challenges and Perseverance. Pathogens, 13(4). https://doi.org/10.3390/pathogens13040323
Macklin, G. R., Goel, A. K., Mach, O., Tallis, G., Ahmed, J. A., O’Reilly, K. M., Grassly, N. C., & Diop, O. M. (2023). Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020. Vaccine, 41, A19–A24. https://doi.org/10.1016/j.vaccine.2022.08.008
Macklin, G. R., Peak, C., Eisenhawer, M., Kurji, F., Mach, O., Konz, J., Gast, C., Bachtiar, N. S., Bandyopadhyay, A. S., & Zipursky, S. (2023). Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): novel oral polio vaccine type 2 (nOPV2) experience. Vaccine, 41, A122–A127.
Mangal, T. D., Aylward, R. B., Mwanza, M., Gasasira, A., Abanida, E., Pate, M. A., & Grassly, N. C. (2014). Key issues in the persistence of poliomyelitis in Nigeria: A case-control study. The Lancet Global Health, 2(2). https://doi.org/10.1016/S2214-109X(13)70168-2
Martin, J., Burns, C. C., Jorba, J., Shulman, L. M., Macadam, A., Klapsa, D., Majumdar, M., Bullows, J., Frolov, A., Mate, R., Bujaki, E., Castro, C. J., Bullard, K., Konz, J., Hawes, K., Gauld, J., Blake, I. M., Mercer, L. D., Kurji, F., … Zipursky, S. (2022). Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing — Worldwide, March–October 2021. MMWR. Morbidity and Mortality Weekly Report, 71(24), 786–790. https://doi.org/10.15585/mmwr.mm7124a2
Mohammed, A., Datta, K., Jamjoon, G., Magoba-Nyanzi, J., Hall, R., & Mohammed, I. (2009). Report on Barriers to Polio Eradication in Nigeria.
Nasir, U. N., Bandyopadhyay, A. S., Montagnani, F., Akite, J. E., Mungu, E. B., Uche, I. V., & Ismaila, A. M. (2016). Polio elimination in Nigeria: A review. Human Vaccines and Immunotherapeutics, 12(3), 658–663. https://doi.org/10.1080/21645515.2015.1088617
Peak, C. M., Lyons, H., Voorman, A., Gray, E. J., Cooper, L. V., Blake, I. M., Hawes, K. M., & Bandyopadhyay, A. S. (2024). Monitoring the Risk of Type-2 Circulating Vaccine-Derived Poliovirus Emergence During Roll-Out of Type-2 Novel Oral Polio Vaccine. Vaccines, 12(12). https://doi.org/10.3390/vaccines12121308
Porta, M. (2008). A dictionary of epidemiology. Revista Española de Salud Pública, 82(4). https://doi.org/10.1590/s1135-57272008000400008
Rachlin, A., Patel, J. C., Burns, C. C., Jorba, J., Tallis, G., O’Leary, A., Wassilak, S. G. F., & Vertefeuille, J. F. (2022). Progress Toward Polio Eradication — Worldwide, January 2020–April 2022. MMWR. Morbidity and Mortality Weekly Report, 71(19), 650–655. https://doi.org/10.15585/mmwr.mm7119a2
Sun, Y., Keskinocak, P., Steimle, L. N., Kovacs, S. D., & Wassilak, S. G. (2024). Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria. Vaccine: X, 18. https://doi.org/10.1016/j.jvacx.2024.100476
Tesfaye, B., Chia, J. E., Nomhwange, T., Owuor, D. C., Muluh, T. J., Nosheen, S., Wakem, A. Y. D., Jimoh, A., Saatcioglu, A., Touray, K., Hamisu, A. W., Ndoutabe, M., Ahmed, J. A., & Kfutwah, A. (2025). Epidemiology and genetic characterization of orphan polioviruses in Africa, 2022–2024: Unmasking silent transmission and implications for eradication. Vaccine: X, 27. https://doi.org/10.1016/j.jvacx.2025.100752
Thompson, K. M., & Badizadegan, K. (2024). Evolution of global polio eradication strategies: targets, vaccines, and supplemental immunization activities (SIAs). Expert Review of Vaccines, 23(1), 597–613. https://doi.org/10.1080/14760584.2024.2361060
Voorman, A., Lyons, H., Shuab, F., Adamu, U. S., Korir, C., Erbeto, T., Bandyopadhyay, A. S., & Okiror, S. (2023). Evaluation of novel oral polio vaccine type 2 SIA impact in a large outbreak of circulating vaccine-derived poliovirus in Nigeria. The Journal of Infectious Diseases. https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad222/7207511
Voorman, A., O’Reilly, K., Lyons, H., Goel, A. K., Touray, K., & Okiror, S. (2023). Real-time prediction model of cVDPV2 outbreaks to aid outbreak response vaccination strategies. Vaccine, 41, A105–A112. https://doi.org/10.1016/j.vaccine.2021.08.064
WHO. (2004). Polio laboratory manual. WHO Library, 4(August), 157. http://apps.who.int//iris/handle/10665/68762
WHO. (2017). WHO Guidelines on Ethical Issues in Public Health Surveillance. Sustainability (Switzerland), 11(1), 1–14. http://scioteca.caf.com/bitstream/handle/123456789/1091/RED2017-Eng-8ene.pdf?sequence=12&isAllowed=y%0Ahttp://dx.doi.org/10.1016/j.regsciurbeco.2008.06.005%0Ahttps://www.researchgate.net/publication/305320484_SISTEM_PEMBETUNGAN_TERPUSAT_STRATEGI_MELESTARI
WHO. (2021). Vaccine-derived poliovirus: laboratory surveillance manual. https://www.who.int/publications/i/item/9789240021799
WHO. (2022). Global Polio Eradication Initiative. Surveillance for poliomyelitis: guidelines for AFP and environmental surveillance. https://polioeradication.org/wp-content/uploads/2022/06/GPEI-Surveillance-Guidelines-2022.pdf
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is an open-access journal and articles are distributed under the terms of the Creative Commons Attribution Non-Commercial Share-Alike License 4.0. This licence allows users to download and share, remix, tweak and build upon the article for non-commercial purposes, so long as the original authorship is acknowledged and the new creations are licensed under identical terms.